A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy(†)

Patients with (a) recurrent malignant glioma (MG): glioblastoma (GBM) or recurrent anaplastic glioma (AG), and (b) nonprogressive (NP) GBM following radiation therapy (RT) were eligible. Primary objective for recurrent MG was progression-free survival at 6 months (PFS-6) and overall survival at 12 m...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Raizer, Jeffrey J., Abrey, Lauren E., Lassman, Andrew B., Chang, Susan M., Lamborn, Kathleen R., Kuhn, John G., Yung, W.K. Alfred, Gilbert, Mark R., Aldape, Kenneth A., Wen, Patrick Y., Fine, Howard A., Mehta, Minesh, DeAngelis, Lisa M., Lieberman, Frank, Cloughesy, Timothy F., Robins, H. Ian, Dancey, Janet, Prados, Michael D.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2010
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2940554/
https://ncbi.nlm.nih.gov/pubmed/20150372
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nop015
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados